Givinostat (hydrochloride monohydrate)

732302-99-7

C24H30ClN3O5

DMSO : >= 100 mg/mL (210.10 mM)

Epigenetics; Cell Cycle/DNA Damage

Givinostat hydrochloride monohydrate (ITF-2357 hydrochloride monohydrate) is a HDAC inhibitor with an IC₅₀ of 198 and 157 nM for HDAC1 and HDAC3, respectively. IC50 & Target: IC50: 198 nM (HDAC1), 157 nM (HDAC3)^[1], 10 nM (HD2), 7.5 nM (HD1-B), 16 nM (HD1-A)^[3] In Vitro: Givinostat (ITF2357) suppresses total LPS-induced IL-1beta production robustly compared with the reduction by ITF3056. At 25, 50, and 100 nM, Givinostat reduced IL-1beta secretion more than 70%. Givinostat (ITF2357) suppresses the production of IL-6 in PBMCs stimulated with TLR agonists as well as the combination of IL-12 plus IL-18. IL-6 secretion decreases to 50% at 50 nM Givinostat (ITF2357), but at 100 and 200 nM, there is no reduction^[1]. As shown by the CCK-8 assay, Givinostat (ITF2357) inhibits JS-1 cell proliferation in a concentration-dependent manner. Treatment with Givinostat (ITF2357) >=500 nM is associated with significant inhibition of JS-1 cell proliferation (P<0.01). Also, the cell inhibition rate significantly differs between the group cotreated with Givinostat >=250 nM plus LPS and the group without LPS treatment (same Givinostat concentration) (P<0.05)^[2]. In Vivo: Givinostat (ITF2357) at 10 mg/kg is used as a positive control and, as expected, reduced serum TNFalpha by 60%. Strikingly, pretreatment of ITF3056 starting at 0.1 mg/kg significantly reduces the circulating TNFalpha by nearly 90%. To achieve a significant increase in serum IL-1beta production, a higher dose of LPS is injected (10 mg/kg), and blood is collected after 4 h. Similarly, when pretreated with lower doses of Givinostat (ITF2357) (1 or 5 mg/kg), there is a 22% reduction for 1 mg/kg and 40% for 5 mg/kg^[1].